Granted Patent B2

US 12,435,088 · App. 17/416,976 · Granted Oct 7, 2025

Inventors: Derek Shieh Tan (New York, NY); Lisa Charlotte Standke (New York, NY); Luis Edmundo Nereo Quadri (New York, NY); Glennon Valere Bythrow (Chicago, IL); William Ramses Bishai (Baltimore, MD); Shichun Lun (Ellicott City, MD)

Assignees: Memorial Sloan-Kettering Cancer Center; Research Foundation of the City University of New York; The Johns Hopkins University

C07D473/30C07D473/18

Abstract

Claims (50)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R 1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl;

each or R 2 and R 3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, —NO 2 , —CN, —OR e , —N(R e ) 2 , —N 3 , —SO 2 H, —SO 3 H; —SH, —SR e , —SSR e , —OC(═O)R e , —OCO 2 R e , —OC(═O)N(R e ) 2 , —C(═O)N(R e ) 2 , —NC(═O)N(R e ) 2 , —OC(═O)O(R e ) 2 , —SO 2 R e , —SO 2 OR e , —OSO 2 R e , —S(═O)R e , or —OS(═O)R e ;

each of R 9 , R 10 , R 11 and R 12 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, —NO 2 , —CN, —OR 4 , —OR 5 , —OR e , —N(R e ) 2 , —N 3 , —SO 2 H, —SO 3 H; —SH, —SR e , —SSR e , —OC(═O)R e , —OCO 2 R e , —OC(═O)N(R e ) 2 , —OC(═O)N(R e ) 2 , —C(═O)N(R e ) 2 , —NC(═O)N(R e ) 2 , —OC(═O)O(R e ) 2 , —SO 2 R e , —SO 2 OR e , —OSO 2 R e , —S(═O)R e , —OS(═O)R e , or two occurrences of any R 9 , R 10 , R 11 and R 12 are joined to form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring;

each of R 4 and R 5 is independently hydrogen, optionally substituted C 1-6 alkyl, optionally substituted acyl, or an oxygen protecting group, or R 4 and R 5 are joined to form an optionally substituted heterocyclic ring;

X 1 is a bond, —O—, —(C(R d ) 2 ) q —, or —NR e —;

each occurrence of R d is independently hydrogen, halogen, optionally substituted C 1-6 alkyl, —OR e , or —N(R e ) 2 ;

each occurrence of R e is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or two R e are joined to form an optionally substituted carbocyclic, an optionally substituted aryl, an optionally substituted heterocyclic or optionally substituted heteroaryl ring;

q is 1, 2, or 3;

each occurrence of R 7 is independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, —NO 2 , —CN, —OR e , or —N(R e ) 2 , or two R 7 are joined to form an optionally substituted aryl or optionally substituted heteroaryl ring; and

n is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1 , wherein the compound is of formula:

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

3. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

4. A method of treating or preventing an infectious disease comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.

5. A method of inhibiting siderophore biosynthesis in an infection in a subject, the method comprising administering to the subject a compound of claim 1 .

6. A method of inhibiting siderophore biosynthesis in an infectious microorganism, the method comprising contacting the infectious microorganism with a compound of claim 1 .

7. A method of inhibiting biosynthesis of a virulence factor in an infection in a subject, the method comprising administering to the subject a compound of claim 1 .

8. A method of inhibiting biosynthesis of a virulence factor in an infectious microorganism, the method comprising contacting the infectious microorganism with a compound of claim 1 .

9. A kit comprising:

a compound of claim 1 ;

and instructions for administering to a subject the compound or composition.

10. The compound of claim 1 , wherein the compound is of the Formula (III-B):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

11. The compound of claim 1 , wherein the compound is of the Formula (III-C):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

12. The compound of claim 1 , wherein the compound is of the Formula (III-D):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

13. The compound of claim 1 , wherein the compound is of the Formula (III-E):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.

14. The compound of claim 1 , wherein the compound is of the Formula (IV-L):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R 8 is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, oxygen protecting group, or a nitrogen a protecting group; and

n is 0, 1, 2, 3, or 4.

15. The compound of claim 1 , wherein the compound is of the Formula (IV-M) or Formula (IV-N):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

R 8 is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, oxygen protecting group, or a nitrogen a protecting group; and

n is 0, 1, 2, 3, or 4.

16. The compound of claim 1 , wherein the compound is of the Formula (IV-T):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

each occurrence of R 8 is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, oxygen protecting group, or a nitrogen a protecting group, or two R 8 are joined to form an optionally a substituted heterocyclyl, or optionally substituted heteroaryl ring; and

n is 0, 1, 2, 3, or 4.

17. The compound of claim 1 , wherein the compound is of the Formula (IV-U) or Formula (IV-V):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:

each occurrence of R 8 is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, oxygen protecting group, or a nitrogen a protecting group, or two R 8 are joined to form an optionally a substituted heterocyclyl, or optionally substituted heteroaryl ring; and

n is 0, 1, 2, 3, or 4.

18. The compound of claim 1 , wherein R 1 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, cyclopropyl, and trifluoromethyl.

19. The compound of claim 1 , wherein each occurrence of R e is hydrogen.

20. The compound of claim 1 , wherein the phenyl ring bearing R 7 is of formula:

Assignments (4)

Continuity (2)

References Cited (184)